Introduction migration and invasion [16, 17] . The GTP-binding Ras-like protein 2 (Di-Ras2) is one of GTPases 76 forming a distinct subgroup of the Ras family, and shares 30-40% overall identity with other 77 members of the Ras family [18, 19] . Di-Ras2 forms a tight complex with SmgGDS in cytosol, 78 which lowers its affinity for guanine nucleotides [20] . Analyses using Oncomine and The Cancer 79 Genome Atlas (TCGA) databases show that mRNA expression levels of Di-Ras2 are significantly 80 up-regulated in some tumors, especially ccRCC. However, little is known about the biological 81 role(s) of Di-Ras2 or how their activities are regulated in ccRCC. 82 ccRCC is genetically characterized by a frequent loss or mutation of von Hippel-Lindau 83 (VHL) tumor suppressor gene, which appears to be the most important gene for the formation and 84 progression of ccRCC [1, 5, 21] .The tumor-suppressive effect of VHL protein comes from its 85 function as an E3 ubiquitin ligase complex substrate recognition element [22, 23] .Moreover, VHL 86 takes part in the ubiquitin-proteasome pathway (UPP) to control steady-state protein level of 87 several effectors in ccRCC [24, 25] . Although Hypoxia-inducible factor α-subunit (HIF) is the 88 most studied gene interacting with VHL [26] [27] [28] , recent studies also showed that VHL can interact 89 with several other oncogenic proteins and facilitates their ubiquitination and degradation in 90 ccRCC, such as Jade family PHD finger 1 (Jade-1) [29] [30] [31] ,Zinc fingers and homeoboxes 2 91 (ZHX2) [32] , protein phosphatase 5 (PP5) [33] , Aurora kinase A (AURKA) [34] , and atypical 92 protein kinase C (PKC) [35] . Moreover, VHL has also been reported to regulate the epigenetic 93 landscape of renal cancer by binding and degrading the hyperphosphorylated Rpb1 [36] . Therefore, 94 according to its multifunction, von Hippel-Lindau (VHL) is highly related to ccRCC by enhancing 95 the ubiquitination and degradation of certain oncogenes. However, whether and how VHL can 6 directly interact with the MAPK pathway is unclear. 97
In the present study, we sought to characterize the physiological properties of Di-Ras2 98 proteins in ccRCC. To this end, we employed a plasmids-mediated overexpression and 99 knockdown system to determine Di-Ras2's function in ccRCC. We found that Di-Ras2 promoted 100 ccRCC proliferation by activating the MAPK pathway in the absence of von Hippel-Lindau 101 (VHL), which can facilitate the ubiquitination and degradation of Di-Ras2. We thus propose that 102
Di-Ras2 is a potential oncogene and biomarker in ccRCC, and these data provide us a new view of 103 the relationship of VHL and the MAPK pathway in ccRCC tumorigenesis. 104
Di-Ras2 expression is up-regulated in ccRCC 106
To determine the significance of Di-Ras2 in ccRCC, we first analyzed multiple microarray data 107 sets in the Oncomine and TCGA databases. There were about 100 genes differentially expressed in 108 human kidney tumor samples as compared to the adjacent normal kidney tissues. Among them, 109
Di-Ras2 exhibited the most significant up-regulation in ccRCC samples ( Supplementary Fig. S1 ). 110
As shown in Figs. 1A-F, Di-Ras2 mRNA levels were increased significantly in human tumor 111 samples as compared to the adjacent normal kidney tissues. 112
To verify the microarray analysis results, we performed q-PCR, Western blotting, and IHC 113 staining on human ccRCC specimens and their matched normal tissues. Data showed that mRNA 114 and protein expression levels of Di-Ras2 were significantly higher in renal cell carcinoma 115 signaling, we hypothesized that Di-Ras2may promote tumor growth through the MAPK pathway. 151
Indeed, in the absence of VHL, Di-Ras2 promoted the phosphorylation of several MAPK pathway 152 signal factors, such as MAPK, JNK, and P38 in 786-O cells. However, the MAPK pathway could 153 not be activated by Di-Ras2 in CAKI-1 cells (wild type VHL) ( Fig. 4A ). In addition, we 154 performed IHC and WB on xenograft tumor sections and samples as indicated in Fig. 3 , and 155 obtained the same results (Figs. 4B and 4C). These data confirmed that Di-Ras2 can promote the 156 cascade reaction in the MAPK pathway in VHL-mutated ccRCC. To further validate the 157 suppressive role of VHL in the activation of the MAPK pathway induced by Di-Ras2, we 158 overexpressed VHL in 786-O cells and knocked down VHL in CAKI-1 cells. As shown in Fig. 4D , 159
Di-Ras2 activated the MAPK signaling pathway in VHL-mutated 786-O cells, while this function 160 was blocked by exogenous VHL. Meanwhile, the activation of MAPK signaling pathway was 161 restored after knockdown of VHL in Di-Ras2-transfected CAKI-1 cells (wild type VHL). 162 Surprisingly, we found that protein levels of both exogenous and endogenous Di-Ras2 was 163 decreased when levels of VHL were elevated and was increased when levels of VHL were 164
declined (Figs. 4D and 4E). 165
To further substantiate the suppressive role of VHL in the regulation of Di-Ras2, we 166 investigated ectopic VHL expression on Di-Ras2 in 293T cells and CAKI-1 cells. In line with our 167 hypothesis, protein levels of Di-Ras2 reduced proportionally when VHL levels were progressively 168
augmented, suggesting that VHL negatively regulates Di-Ras2 abundance in a dose-dependent and 169 time-dependent manner (Figs. 4F and 4G).
10

VHL interacts with Di-Ras2 and enhances the ubiquitination and degradation of Di-Ras2 172
Increasing evidence indicates that the E3 ligase plays an important role in oncogenesis and cancer 173 development by controlling protein levels that regulate multiple biological processes [38] . Given 174 that VHL is a type of E3 ligase, we next investigated the molecular mechanism through which 175 VHL promoted Di-Ras2 degradation. As shown in Fig. 5A , the half-life of Di-Ras2 protein was 176 shortened significantly in 293T and CAKI-1 cells transfected with VHL after using cycloheximide 177 (CHX), indicating that VHL negatively affects Di-Ras2 stability. In addition, as shown in Fig. 5B , 178
we observed that treatment with MG132, a proteasome inhibitor, led to a significant lengthening 179 of the Di-Ras2 protein half-life, supporting the notion that VHL regulates Di-Ras2 stability by 180 proteasome-mediated mechanisms. 181
Given that protein-protein interaction is essential for E3 ligase to act on its substrates, we 182 next explored whether VHL interacts with Di-Ras2. Co-immunoprecipitation results showed that 183 both exogenous and endogenous VHL bound to Di-Ras2 in 293T cells and CAKI-1 cells (Figs. 5C 184 and 5D). Considering that VHL protein serves as an E3 ligase, we hypothesized that VHL 185 promoted Di-Ras2 protein ubiquitination. In agreement with our hypothesis, we observed that the 186 ubiquitination of both exogenous and endogenous Di-Ras2 was augmented by VHL 187 overexpression, whereas they were diminished by VHL knockdown in 293T cells and CAKI-1 188 cells respectively ( Fig. 5E ). To confirm the interaction between VHL and Di-Ras2, we employed 189 immunofluorescent staining on Di-Ras2 and VHL. The results showed that they were co-localized 190 in CAKI-1 cells. (Fig. 5F ). Collectively, our data suggest that VHL binds to Di-Ras2 and enhances 191 its ubiquitination and degradation.
The tumor-promoting activity of Di-Ras2 is overridden by VHL. 194
To verify the suppressive role of VHL in Di-Ras2-induced ccRCC progression, we then employed We also tested the Di-Ras2 stability in hypoxia condition, which is closely related to VHL. 210
The results showed that the ubiquitination of Di-Ras2 was augmented by VHL overexpression in 211 Given our observations that Di-Ras2 can upregulate the MAPK pathway in human ccRCC and 215 that VHL negatively regulated Di-Ras2 protein stability, we re-analyzed the TCGA RPPA data and 216 found that the phosphorylation level of p38MAPK was significantly up-regulated in VHL-mut and 217 DIRAS2-high ccRCC samples, which implicates an activation of the MAPK pathway in these 218 samples ( Fig. 7A ). Further analyses showed a weak inverse correlation between the mRNA levels 219
of Di-Ras2 and that of VHL in ccRCC samples from TCGA database (Fig. 7B ). We also compared 220 The small GTPase Ras family proteins are appreciated as potential candidates in many cancers. 230 VHL is a multifunctional protein and has been closely associated with ccRCC. To date, the 246 most well-characterized function of VHL is its role as an E3 ubiquitin ligase that participates in 247 the degradation of some oncogenic effectors. Of the several targets mentioned above, the 248 regulation of the protein stability of HIFs is the most recognizable activity of VHL [35, 36, 45] . 249 enriched in ccRCC cells in which VHL is lost or mutated [32, 46] . We showed in current study a 251 potential target of VHL, Di-Ras2, and revealed a role of VHL in the regulation of ccRCC 252 formation through the Ras/MAPK pathway. VHL physically binds to Di-Ras2 and enhances its 253 
RNA isolation and quantitative RT-PCR 278
Total RNA was isolated from cultured cells or fresh samples with Trizol reagent (Invitrogen). 
Immunofluorescent and immunohistochemistry (IHC) assays 301
To prepare slides of ccRCC cell lines for immunofluorescent staining, cells were plated on cover 302 slides in 24-well plates and allowed to grow for 24 hours. The slides were then fixed in 4% 303 formalin for 15 minutes at 4˚C and rinsed by PBS three times. The cover slides were first treated 304 with 0.5％ Triton for 10 minutes and blocked with 10% goat serum at room temperature for 1 305 hour. Primary antibody incubations were performed overnight at 4°C. After extensive washing 306 with PBS, secondary antibody was applied to the sections at room temperature for 1 hour. Slides 307 were washed with PBS three times and then mounted with Vectashield mounting medium (Vector 308 laboratories, Inc. H-1200). Primary antibody against Di-Ras2 (Abcam, ab67430) and VHL (SAB 309 #32075) were used. 310
For IHC staining, paraffin-embedded ccRCC tissues were deparaffinized, rehydrated, and 311 subjected to a heat-induced epitope retrieval step by treatment with 0.01M sodium citrate (pH 6.0). 312
The sections were then incubated with 0.3% Triton X-100 in PBS (137 mM NaCl, 2.7 mM KCl, 314 10 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 , pH 7.4) for 15 minutes, followed by 10% goat serum in PBS 315 for 1 hour. Subsequently, samples were incubated with a mouse polyclonal Di-Ras2 antibody 316 (Abcam, ab67430), diluted at 1:500 in 1% goat serum for 1 hour at 37°C. After three washes in 317 PBS, sections were incubated with an HRP-conjugated secondary antibody for 1 hour at room 318 temperature. Sections were counterstained with hematoxylin. Three random immunostaining 319 images of each specimen were captured using a Leica DM2500 microscope and analyzed by 320
Image-Pro Plus 6.0 software. 
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